Member Info for sphinx100

https://www.marketwatch.com/story/provexis-partners-with-by-health-for-fruitflow-product-shares-rise-271636026047

And probably the most important bit of news being . ‘. · Provexis and By-Health will seek to collaborate on research and development projects which may result in the development and approval of Fruitflow as a drug, for potential sale and distribution in the Territories.

Fruitflow is currently produced by outsourced third party manufacturers in Europe, and it is intended that the Company will have direct access to these manufacturers for its sales of Fruitflow to third parties. The Company and the third party manufacturers are actively engaged in some ongoing production capacity planning, looking at the steps required to scale-up the production of Fruitflow to meet the anticipated increase in demand.

Another strong quarter http://www.by-health.com/en/aboutus/news/4404/

Looks like someone lost patience !

https://www.cirs-reach.com/news-and-articles/Guideline-on-Health-Food-Exportation-to-China.html

Another patent for US , bit earlier. https://patentscope.wipo.int/search/en/detail.jsf?docId=US332609534&_cid=P11-KUE8D1-13823-4

Published 30/9/21. https://patentscope.wipo.int/search/en/detail.jsf?docId=US337428323&_cid=P11-KUDYNB-34180-1

1 October 2021
Provexis plc
('Provexis' or the 'Company')

Grant of Share Options

Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces that it has today awarded a total of 10,000,000 options ('Options') over ordinary shares of 0.1 pence each in the Company ('Ordinary Shares') under the Provexis 2005 share option scheme to certain scientific, sales and marketing consultants to the Company.

These Options will have an exercise price of 0.80 pence, being the closing mid-market price on 30 September 2021. The Options are exercisable, subject to vesting, between 1 April 2024 and 10 years from the date of grant.

Following the issue of the new Options, the total number of Ordinary Shares under option which could be issued if all of the performance criteria are met is 178,500,000 Ordinary Shares, representing 8.1 per cent. of the Company's issued share capital.


For further information please contact:

Provexis plc
Ian Ford, CEO
Dawson Buck, Chairman


Tel: 07490 391888

Talks with DSM, who knows where that will end ? All good as far as I can see .

The only reason to leave finals to the last day is that they are giving every chance for the Blue hat to be announced imo , so I am not expecting anything spectacular maybe 10 or 20% more than last year + anything from BY health for research . Maybe something is in the pipeline , i only hope the year after year cycle of refinancing has come to an end .

You would think it has been completed ! As you say the £8k was paid last year and we were expected to get the £55k+ last year , even taking covid into account that’s a long time to complete one research project .

Gixer shouldn’t we get the ff+nitrates money from By-health (£47k) in these coming results , I also wonder if any other research projects have been commissioned from byhealth , but who knows with pxs and results .

Another stellar performance I never H1. Up 42%. http://www.by-health.com/en/aboutus/news/4342/

But no mention of ff. https://www.by-health.com/en/aboutus/news/4329/

Website updated. https://www.provexis.com/?news=fruitflow-and-its-relationship-with-covid-19-afc-lifescience-sop-subarashi

Maybe something else By-health should look into . https://www.dailymail.co.uk/sciencetech/article-9749419/Aspirin-cut-risk-death-cancers-20-study-finds.html

https://www.provexis.com/news/

It seems a lot of ff products are out of stock , I hope it’s because there is good demand for the products and not supply problems , https://china.desertcart.com/products/44966552-consumption-of-fruitflow-in-8-human-trials-proven-to-maintain-healthy-platelet-and-improve-blood-flow-heart-and-cardiovascular-health

https://hologramsciences.com/